Tag: cardiovascular

1. In this cohort study, there was a dose-dependent association between enzyme-inducing antiseizure medication use and an elevated hazard of incident cardiovascular disease. 2. Short-term enzyme-inducing antiseizure medication therapy did not confer considerable risk, but caution should be used when taking these medications long-term, particularly in patients with late-onset epilepsy. Evidence...

1. The risk of developing atrial fibrillation was significantly greater in athletes compared to non-athletes. 2. Younger (<55 yrs) and mixed sport athletes had a greater risk of developing atrial fibrillation than older athletes and those participating in endurance sports respectively. Evidence Rating Level: 1 (Excellent) Many studies have shown that exercise...

1. In this study, improved sleep quality was associated with significantly decreased systolic blood pressure and increased high-density lipoprotein levels after 24 months. 2. Increased time to sleep was also associated with decreased low-density lipoprotein levels, after 24 months. Evidence Rating Level: 1 (Excellent) Sleep has endocrinologic implications, which may impact cardio-metabolic health....

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills combining...

1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...

1. Combined use of intracoronary near-infrared spectroscopy (NIRS) and intravascular ultrasound were effective at detecting untreated intracoronary lesions at high risk of major adverse cardiac event (MACE). 2. Highly lipidic lesions and large plaque burden were found to be independent predictors of non-culprit lesion-related MACEs. Evidence Rating Level: 2 (Good) Study Rundown:...

1. Stopping renin-angiotensin system inhibition in patients with advanced chronic kidney disease was associated with higher risk of mortality, major cardiovascular events, and lower risk of kidney replacement therapy. Evidence Rating Level: 2 (Good) Studies have shown that renin-angiotensin system inhibitors (RASi) are effective in delaying chronic kidney disease (CKD) progression. Angiotensin-converting enzyme...

1. Positive fecal immunochemical test (FIT) results were associated with increased incidences of ischemic stroke, myocardial infarction, and all-cause mortality. Evidence Rating Level: 2 (Good) While fecal immunochemical tests (FIT) is a commonly used and effective screening tool for colorectal cancer (CRC), their clinical use in detecting other diseases is poorly known....